Third Harmonic Bio — Investor Presentation (October 2022)
20 slides from Third Harmonic Bio's investor presentation, Oct 11, 2022
Slide 1: Advancing the Next Wave of Medicine for Allergy and Inflammation
Advancing the Next Wave of Medicine for Allergy and Inflammation ©2022 THIRD HARMONIC BIO OCTOBER 2022 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. Any statements made in this presentation that are not statements of historical fact, inclu
Slide 3: Pipeline-in-a-Product Potential: THB001 Selective Oral KIT Inhibitor
“Pipeline-in-a-Product” Potential THB001: Selective Oral KIT Inhibitor KIT: A Novel, Clinically Validated Target Large Established Markets With High Unmet Need Third Harmonic Bio: clinical-stage company with oral wild-type KIT inhibitor to treat mast cell-mediated diseases Millions of patients livin
Slide 4: Mast Cells are a Fulcrum of Allergy and Inflammation
Receptor-binding agonists IgE Complement Neuropeptides Microbial products Cytokines TSLP Chemokines Physical activators Temperature Pressure Cell-cell contact Pre-formed Mediators Histamine IL-4, IL-13 TNF, GM-CSF Proteases Serotonin Heparin Newly Synthesized Mediators Prostaglandins Leukotrienes Cy
Slide 5: Chronic Urticaria Disease Overview
Prevalence: More than 1.5 million patients or 0.5-1% point prevalence; ~70-80% female, mean age ~46 years Symptoms: severely itchy, painful wheals and angioedema which confer significant mental health and quality of life burdens Etiology: both inducible (caused by specific stimuli/triggers) and spon
Slide 6: Severe Asthma Disease Overview
Severe Asthma Disease Overview Limited oral treatment options for patients beyond corticosteroids and anti-leukotrienes Prevalence: ~5-10% of all asthma patients; estimated 750K – 1 million patients in US; adult population ~60% female, mean age ~50 years Definition: disease not sufficiently controll
Slide 7: Targeting KIT Has Been Shown To Broadly Inhibit Mast Cell Activity
Targeting KIT Has Been Shown To Broadly Inhibit Mast Cell Activity Demonstrated clinical efficacy in chronic spontaneous urticaria Master regulator of mast cell proliferation, migration, activation and survival Inhibition of KIT drives both mast cell inactivation and depletion KIT (CD117) Barzovolim
Slide 8: THB001: Highly Selective Oral Wild-Type KIT Inhibitor
THB001: Highly Selective Oral Wild-Type KIT Inhibitor Potent KIT inhibitor High kinome selectivity Depleted mast cells in relevant GI, skin and lung tissues of rats and dogs Demonstrated efficacy in rat models of dermal anaphylaxis and asthma Favorable pharmacokinetic profile including high oral bio
Slide 9: Phase 1a Trial Design
Phase 1a Trial Design THB001: Phase 1 SAD/MAD/Food Effect in Healthy Volunteers Single Ascending Dose (n=42) Healthy Male/Female, 18-65 yrs Plasma PK 300mg 600mg 400mg FED 30mg 100mg 10mg Multiple Ascending Dose x 14 Days (n=32) Healthy Vasectomized Male/Female 18-65 yrs Plasma/Urine PK Pharmacodyna
Slide 10: THB001 PK Summary: Unbound Trough Values vs KIT Cellular IC50
Unbound THB001 Trough Values vs KIT Cellular IC50 200mg QD: ~1.5-2-fold 200mg BID: ~10-fold 500mg QD FED: ~10-fold 400mg BID: ~20-fold Mean t1/2 ~24 hours THB001 Multiple Dose PK (14 days) Study Day [Trough Plasma THB001](ng/mL) KIT cellular IC50 1 200mg QD 200mg BID 400mg BID 500mg QD FED End of tr
Slide 11: THB001 Phase 1a Adverse Events Summary
THB001 200mg QD 200mg BID 500mg QD FED 400mg BID PBO Preferred Term, n % 6 % of (n) 6 % of (n) 6 % of (n) 6 % of (n) 8 % of (n) Hair Color Changes 2 33.3% 6 100.0% 4 66.7% 5 83.3% — — Headache 2 33.3% 2 33.3% 4 66.7% 2 33.3% 3 37.5% Nausea 1 16.7% 2 33.3% 2 33.3% — — 2 25.0% Diarrhea 1 16.7% 1 16.7%
Slide 12: THB001 Hematology – Mean Neutrophil Count
THB001 Hematology – Mean Neutrophil Count (+/- SD) Placebo multiple dose 200mg THB001 multiple dose QD 200mg THB001 multiple dose Q12H 400mg THB001 multiple dose Q12H 500mg THB001 multiple dose QD FED ULN LLN ULN=upper limit of normal; LLN=lower limit of normal Mean ± SD Study Day Neutrophils (109/L
Slide 13: Hematology Parameter Comparison – THB001 and Barzovolimab in NHVs
Hematology Parameter Comparison –THB001 and Barzovolimab in NHVs THB001 200mg QD 200mg BID 400mg BID 500mg QD FED PBO Leukocytes (109/L) - WBC -0.6 (1.2) -0.7 (1.3) -1.9 (1.0) -1.3 (1.4) -0.5 (0.6) Erythrocytes (1012/L) - RBC -0.3 (0.3) -0.3 (0.2) -0.5 (0.1) -0.4 (0.3) -0.04 (0.2) Hematocrit (%) -0.
Slide 14: THB001 PD Summary: Serum Tryptase
THB001 PD Summary: Serum Tryptase Serum Tryptase Normalized to Baseline Over Time LLOQ PBO 200mg QD 200mg BID 400mg BID 500mg QD FED PBO 400mg BID LLOQ=lower limit of quantitation; Mean ± SD PBO = placebo Serum Tryptase (% Baseline) Study Day End of treatment Mean Absolute Serum Tryptase Over Time S
Slide 15: Phase 1b Chronic Inducible Urticaria Study Design
Phase 1b Chronic Inducible Urticaria (CIndU) Study Design Design Open label, dose escalation design 3 doses (1:1:1) of THB001 (total N=30) for 12 weeks on treatment Generally healthy male and female patients aged 18-75 with Dx’d Cold Induced Urticaria Objectives Safety and Tolerability Mean reductio
Slide 16: THB001·HCl salt outperforms free base in NHV bio-comparison study
THB001·HCl salt outperforms free base in NHV bio-comparison study Significant increase in exposure with THB001 salt Favorable PK profile Supports potential for QD dosing Manufacturing underway to introduce into upcoming clinical studies – no additional tox/clinical requirements to support transition
Slide 17: Indication Expansion: Severe Asthma
Indication Expansion: Severe Asthma Moderately potent KIT inhibitor 43% reduction in serum tryptase --> significant improvements in FEV1 and airway hyperreactivity Non-endotype restricted study population Provides human PoC, even with suboptimal KIT inhibition Cahill, et al., NEJM, May 2017 Gleevec
Slide 18: Phase 1b Inducible Allergic Asthma POC Trial Concept Design
Phase 1b Inducible Allergic Asthma POC Trial Concept Design Design Summary Study Design: Parallel, Blinded, PBO controlled, 2-3 THB001 doses + PBO (1:1:1): N=~10-15/arm Patient Population: mild, stable allergic asthmatic subjects, not on regular anti-inflammatory treatment Primary Endpoint: change f
Slide 19: Anticipated Milestones
Anticipated Milestones ANTICIPATED MILESTONES Phase 2H’22 1H’23 2H’23 1H’24 2H’24 Chronic inducible urticaria Phase 1b Asthma Phase 1b Chronic spontaneous urticaria Phase 2 THB001: Multiple Upcoming Clinical Catalysts Trial initiation Data Readout Regulatory Submission2 Regulatory Submission1 Data R
Slide 20: Advancing the Next Wave of Medicine for Allergy and Inflammation
Advancing the Next Wave of Medicine for Allergy and Inflammation ©2022 THIRD HARMONIC BIO
Third Harmonic Bio — Investor Presentation (October 2022) on 6ix